Obinutuzumab Promotes Renal Preservation in Lupus Nephritis

A post hoc analysis of the NOBILITY trial showed improved outcomes for patients taking obinutuzumab (Gazyva) compared with placebo.
Medscape Medical News

source https://www.medscape.com/viewarticle/998310?src=rss

Comments

Popular posts from this blog

RA and RA-ILD Linked to Higher Lung Cancer Risk

New AAFP practice guideline sets blood pressure targets for adults with hypertension